Breaking News

Ebay to Separate eBay, Paypal Into Independent Companies in 2015

Roche Sues Teva, Sandoz, Dr. Reddy’s Over Generic Aloxi

Roche Holding AG (ROG) filed a lawsuit seeking to block generic-drug companies including Novartis AG (NOVN)’s Sandoz and Teva Pharmaceutical Industries Ltd. (TEVA) from selling a low-cost version of the anti-nausea drug Aloxi.

Sandoz, Teva and Dr. Reddy’s Laboratories Ltd. are seeking U.S. Food and Drug Administration approval to sell generic versions of the medicine. Roche and partner Helsinn Healthcare SA contend the versions would infringe two patents that expire in 2024.

Aloxi, first approved by regulators in 2003, is an injection used to prevent nausea and vomiting caused by surgery or chemotherapy. Roche and Helsinn are seeking a court ruling that would uphold the validity of their patents and block the FDA from granting approval to the copycat medicines.

Sandoz, a unit of Basel, Switzerland-based Novartis, is the world’s second-biggest generic-drug maker, behind Petach Tikva, Israel-based Teva. Dr. Reddy’s, based in Hyderabad, India, is that country’s second-biggest drugmaker.

Roche, based in Basel, and Helsinn, a closely held Swiss company, filed the complaint July 8 in federal court in Newark, New Jersey, claiming they will be “irreparably harmed” by the alleged infringements. The patents were issued on May 24, according to the complaint.

Rachel Zabinski, a spokeswoman for Novartis, said in an e-mail that the company doesn’t comment on pending litigation. Denise Bradley, a Teva spokeswoman, declined to comment. A representative of Dr. Reddy’s didn’t immediately return an e- mail seeking comment.

The case is Helsinn Healthcare v. Dr. Reddy’s Laboratories, 11-cv-3962, U.S. District Court, District of New Jersey (Newark).

To contact the reporters on this story: David Voreacos in Newark, New Jersey, at; Susan Decker in Washington at

To contact the editors responsible for this story: Michael Hytha at; Allan Holmes at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.